Lv6
1820 积分 2024-12-27 加入
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
14天前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
14天前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
14天前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
14天前
已完结
Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma
14天前
已完结
Interpretable machine learning model for predicting perioperative Clavien-Dindo III/IV complications of rectal cancer anterior resection after neoadjuvant therapy: a real-world study
5个月前
已完结
Diagnostic Value of a Global Leadership Initiative on Malnutrition Criteria in Patients with Malignant Tumors: A Systematic Review and Meta-Analysis
5个月前
已完结
Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies
5个月前
已完结
局部进展期直肠癌新辅助放化疗后肿瘤退缩的影响因素分析及预测模型构建
8个月前
已完结
皖公网安备34019202002308
